Sunzen Group Berhad (“Sunzen” or “the Group”), formerly known as Sunzen Biotech Berhad and an established player in Malaysia’s health products, medical devices and services, and loan financing with a diversified portfolio, announced its financial results for the first quarter ended 30 September 2025 (“Q1 FY2026”), delivering a marked turnaround driven by stronger segmental contributions and improved operational efficiency.
The Group recorded revenue of RM19.68 million for Q1 FY2026, compared to RM22.96 million in the corresponding quarter last year. The decline of 14.29% on Year-on-Year (“YoY”) basis was primarily due to reduced export sales of edible bird’s nest.
Despite the softer topline, the Group registered a significantly stronger pre-tax profit of RM3.69 million, surging from RM0.86 million a year ago.
The YoY improvement was mainly underpinned by higher profit contributions from the Loan Financing segment and lower operating expenses in the Human Health segment, alongside contributions from the Medical Devices and Services segment, which was only consolidated into the Group since the quarter ended 31 December 2024.
Quarter-on-quarter (“QoQ”), Sunzen delivered a strong performance. Revenue increased by 31.34%, rising from RM14.98 million in the preceding quarter, driven by improved export performance of edible bird’s nest and stronger segmental contributions.
The Group also achieved a PBT of RM3.69 million, reversing the pre-tax loss of RM0.53 million in Q4 FY2025, which had reflected a one-off bad debt write-off of RM2.97 million.
The sharp QoQ improvement was supported by stronger contributions from the Loan Financing division and better profitability in the Human Health segment following the absence of exceptional items.
Segmental wise, the Human Health segment recorded revenue of RM13.05 million, compared to RM17.65 million a year ago, reflecting a 26.06% YoY decline due to weaker export sales. However, segment profitability improved, with pre-tax loss narrowing markedly to RM0.40 million, from RM0.90 million in the corresponding quarter, following disciplined cost management and lower operating expenses.
The Medical Devices and Services segment continued to build traction, registering RM1.99 million in revenue and RM0.25 million in pre-tax profit for the quarter. No comparative figures were available as the business was acquired only in the second quarter ended 31 December 2024. The segment benefitted from increasing demand for ophthalmic equipment and services, supporting a steady profit trajectory.
The Loan Financing segment continued to demonstrate growth resilience, with revenue rising 41.90% YoY to RM4.64 million from RM3.27 million previously. Pre-tax profit correspondingly increased 44.35% YoY to RM3.45 million, driven by sustained demand for SME financing solutions and stable loan performance.
Group Managing Director of Sunzen Group Berhad, Mr. Teo Yek Ming commented,
“This quarter reflects the underlying strength of our core businesses. The rebound in profitability and the strong QoQ turnaround demonstrate the effectiveness of our operational adjustments, particularly in Human Health, while the Loan Financing and Medical Devices divisions continue to provide consistent earnings momentum. We will maintain our focus on scaling high-growth segments and strengthening our distribution and product capabilities.”
Looking ahead, the Group remains cautiously optimistic. The Loan Financing division is experiencing a slight slowdown in market conditions due to a softer economic backdrop; however, demand and approvals remain stable. The Group is focused on offering flexible, targeted loan packages to sustain competitiveness and support long-term growth.
In the Human Health segment under Ecolite, seasonal strength in Q2 is expected to support stronger order fulfilment. Production and sales for PP bottle bird’s nest drinks have commenced, while the Group expects to deliver its first export order to a new Cambodia customer by December 2025.
Negotiations with retail chains are ongoing as Sunzen continues expanding into the fast-moving consumer goods (“FMCG”) market. The Group is also stepping up digital marketing efforts and increasing participation in trade fairs to capture Chinese New Year-related demand. Concurrently, Sunzen is exploring Original Design Manufacturing (“ODM”) opportunities to diversify beyond its traditional OEM model.
For the Medical Devices and Services segment under Eye Nation Medical, prospects remain favourable as Malaysia’s ophthalmic market continues to expand, supported by rising demand for diagnostic equipment and services.
The Group expects to leverage its strong market positioning and scale efficiently in navigating industry growth, further supported by increased government allocation for healthcare, which rose 2.76% compared to 2025.
Overall, Sunzen remains committed to strengthening its core segments, improving operational efficiencies, and driving sustainable long-term growth across its diversified portfolio. In recognition of its sustained performance, the Board of Directors has declared an interim single-tier dividend of RM0.002 per ordinary share for the financial year ending 30 June 2026.
The dividend will be paid on 12 January 2026 to shareholders whose names appear in the Record of Depositors on 15 December 2025.
For more information, visit www.sunzengroup.com
